Agents for use in the treatment of retinal inflammation
US10519232B2 · kind B2 · utility
1Cited by
3References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 22, 2015 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Jan 22, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to preventive and/or therapeutic agents for use in the treatment of retinal inflammation, and more specifically of Age-related macular degeneration and Retinitis pigmentosa, wherein said agents are selected from an IL-6 inhibitor, an APOE inhibitor and/or a Fas activator as an active ingredient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.